He Fang, Yao Guanping
Key Laboratory of Cell Engineering in Guizhou Province, The Affiliated Hospital of Zunyi Medical University, Zunyi, Guizhou, China.
Department of Reproductive Medicine Center, The Affiliated Hospital of Zunyi Medical University, Zunyi, Guizhou, China.
Stem Cells Int. 2021 Dec 31;2021:4633270. doi: 10.1155/2021/4633270. eCollection 2021.
Ginsenoside Rg1 (Rg1), a purified, active component of the root or stem of ginseng, exerts positive effects on mesenchymal stem cells (MSCs). Many recent studies have found that hematopoietic stem cells (HSCs), which can develop into hematopoietic progenitor cells (HPCs) and mature blood cells, are another class of heterogeneous adult stem cells that can be regulated by Rg1. Rg1 can affect HSC proliferation and migration, regulate HSC/HPC differentiation, and alleviate HSC aging, and these findings potentially provide new strategies to improve the HSC homing rate in HSC transplantation and for the treatment of graft-versus-host disease (GVHD) or other HSC/HPC dysplasia-induced diseases. In this review, we used bioinformatics methods, molecular docking verification, and a literature review to systematically explore the possible molecular pharmacological activities of Rg1 through which it regulates HSCs/HPCs.
人参皂苷Rg1（Rg1）是从人参根或茎中提纯的活性成分，对间充质干细胞（MSCs）具有积极作用。最近许多研究发现，造血干细胞（HSCs）可发育为造血祖细胞（HPCs）和成熟血细胞，它是另一类可受Rg1调节的异质性成体干细胞。Rg1可影响造血干细胞的增殖和迁移，调节造血干细胞/造血祖细胞的分化，并减轻造血干细胞衰老，这些发现可能为提高造血干细胞移植中造血干细胞的归巢率以及治疗移植物抗宿主病（GVHD）或其他由造血干细胞/造血祖细胞发育异常引起的疾病提供新策略。在本综述中，我们运用生物信息学方法、分子对接验证和文献综述，系统地探究Rg1调节造血干细胞/造血祖细胞的可能分子药理活性。
